We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Ofev was previously approved to treat idiopathic pulmonary fibrosis and to slow the rate of decline in pulmonary function among patients with ILD associated with systemic sclerosis or scleroderma. Read More
NICE said the oral therapy would likely save the National Health Service money by reducing the need for an intravenous platelet transfusion and avoiding transfusion-related complications. Read More
FDA Commissioner Stephen Hahn said the transition will open “new pathways for manufacturers to bring products to market,” increasing competition and potentially lowering costs. Read More
The company previously paid $15.4 million to settle two whistleblower lawsuits alleging that Questcor bribed physicians to over-prescribe the gel. Read More